Immutep Limited (IMMP) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.63
↓-67% vs avg
5yr avg: 1.88
30Y Low1.3·High58.6
ROE
↑
-36.9%
↓+4% vs avg
5yr avg: -38.5%
30Y Low-207%·High-26%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMMP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immutep Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $66M | $239M | $241M | $190M | $175M | $234M | $147M | $259M | $339M | $307M | $460M |
| Enterprise Value | $18M | $173M | $81M | $68M | $97M | $177M | $129M | $250M | $322M | $301M | $444M |
| P/E Ratio → | -1.47 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 18.03 | 47.34 | 62.84 | 54.21 | 1027.50 | 60.54 | 19.59 | 1853.75 | 128.69 | 72.81 | 2626.41 |
| P/B Ratio | 0.63 | 1.66 | 1.27 | 1.39 | 1.86 | 3.19 | 4.40 | 10.63 | 10.10 | 11.58 | 13.02 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMMP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.29 | 21.14 | 19.35 | 568.14 | 45.71 | 17.28 | 1789.90 | 122.29 | 71.28 | 2535.85 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
IMMP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Immutep Limited earns an operating margin of -2506.5%. Operating margins have compressed from -2216.0% to -2506.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -36.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1117.6% | -1117.6% | -981.4% | 41.2% | -1111.2% | -346.2% | -200.2% | -11769.3% | -279.8% | 59.7% | -3932.8% |
| Operating Margin | -2506.5% | -2506.5% | -2293.3% | -2216.0% | -19920.0% | -820.0% | -214.0% | -14606.5% | -444.5% | -221.5% | -35117.8% |
| Net Profit Margin | -1218.0% | -1218.0% | -1111.9% | -1138.0% | -18906.5% | -774.1% | -179.9% | -11640.0% | -484.6% | -221.9% | -35426.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.9% | -36.9% | -26.2% | -34.6% | -38.5% | -56.1% | -46.7% | -56.2% | -42.4% | -30.3% | -206.7% |
| ROA | -34.3% | -34.3% | -24.5% | -32.0% | -35.0% | -46.5% | -30.9% | -37.2% | -31.1% | -24.2% | -168.7% |
| ROIC | -176.9% | -176.9% | -303.1% | -387.2% | -160.2% | -148.5% | -76.3% | -95.2% | -47.7% | -35.5% | -237.0% |
| ROCE | -75.4% | -75.4% | -53.6% | -66.6% | -39.4% | -52.8% | -40.8% | -52.1% | -31.0% | -25.5% | -181.6% |
IMMP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $67M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.27 | 0.31 | 0.20 | 0.22 | 0.14 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.46 | -0.85 | -0.90 | -0.83 | -0.78 | -0.52 | -0.37 | -0.50 | -0.24 | -0.45 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -2879.79 | -3808.07 | -367.17 | -3224.10 | -1531.88 | — | — | — | -7497.79 |
Net cash position: cash ($67M) exceeds total debt ($2M)
IMMP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Immutep Limited's current ratio of 11.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.81x to 11.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.69 | 11.69 | 18.25 | 13.81 | 14.16 | 12.81 | 9.26 | 4.44 | 7.43 | 6.05 | 14.72 |
| Quick Ratio | 11.69 | 11.69 | 18.25 | 13.81 | 14.16 | 13.87 | 9.26 | 4.44 | 7.43 | 5.80 | 14.32 |
| Cash Ratio | 10.16 | 10.16 | 17.34 | 12.63 | 12.47 | 11.26 | 7.82 | 3.13 | 6.09 | 4.65 | 14.18 |
| Asset Turnover | — | 0.03 | 0.02 | 0.02 | 0.00 | 0.05 | 0.16 | 0.00 | 0.06 | 0.12 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 2.65 | 11.93 |
| Days Sales Outstanding | — | 0.54 | 718.10 | 830.13 | 17939.78 | 578.68 | 165.36 | 13659.28 | 483.19 | 189.71 | 351.35 |
IMMP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immutep Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $146M | $120M | $90M | $86M | $60M | $41M | $43M | $43M | $43M | $43M |
Peer Comparison
Compare IMMP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMMPYou | $66M | -1.5 | — | — | -1117.6% | -2506.5% | -36.9% | -176.9% | — |
 NKTX | $225M | -2.0 | — | — | — | — | -31.9% | -24.3% | — |
 AGEN | $135M | -1123.5 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 RCUS | $3B | -7.7 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TPVG | $234M | 4.7 | 9.0 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 FHTX | $252M | -3.8 | — | — | 89.2% | -265.6% | — | — | — |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 MRK | $275B | 15.3 | 10.6 | 22.3 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 REGN | $74B | 17.2 | 17.9 | 18.2 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 EXEL | $12B | 17.3 | 13.2 | 14.5 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See IMMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMMP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMMP vs NKTX
Side-by-side business, growth, and profitability comparison vs Nkarta, Inc..
Start ComparisonIMMP — Frequently Asked Questions
Quick answers to the most common questions about buying IMMP stock.
What is Immutep Limited's P/E ratio?
Immutep Limited's current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
What is Immutep Limited's ROE?
Immutep Limited's return on equity (ROE) is -36.9%. The historical average is -69.2%.
Is IMMP stock overvalued?
Based on historical data, Immutep Limited is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Immutep Limited's profit margins?
Immutep Limited has -1117.6% gross margin and -2506.5% operating margin.